RAC - Charts & Price Action, page-25402

There are many ways Bisantrene could be commercialised with varying implications on the SH.

This includes:

- Licensing - were there is no Shareholder decision or forced exit.

- Takeover/sale of Race - (as you suggest) resulting in a shareholder decision to either take cash or take shares in the new owner or a combination of both.

- Sale of the Bisantrene Molecule - Race moves onto other opportunities with other developed molecules. This might require SH approval but no forced sale of shares.

Of course, there will be many opportunities to exit along the way when, and if the shares hit your target price.

@jackherb and many others, including myself, appear to have no intent of leaving money on the table.
The Triangle report and other documentation suggests $25 a share is way too low if Bisantrene is proven and commercialised well.

In the early days it was an accepted RAC agenda to just sell the lot and move on.
With all the new research into BIS and what it can address across most cancer types, I think that narrative has changed.
It appears licensing is the more logical path to commercialisation. Why?

1) Potentially a higher return over a longer period for SHs

2) Bisantrene's benefits needs to be exploited for all cancer types and drug combinations and not hidden inside some big pharma with a narrower focus on its application.

Ultimately the decision is up to the board to advise us on what they believe is the best outcome for shareholders. I'd like to think this decision considers cancer sufferers and the best way to exploit Bisantrene to treat them. I have no doubt whatever what it goes Dr T will have a detailed explanation, supported by facts, as to how they arrived at their decisions.

Good luck to us.